This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rossi, G. P. Articles by Nussdorfer, G. G. Search for Related Content PubMed PubMed Citation Articles by Rossi, G. P. Articles by Nussdorfer, G. G.

Endothelin-1[1–31]: A Novel Autocrine-Paracrine Regulator of Human Adrenal Cortex Secretion and Growth

Departments of Clinical and Experimental Medicine (G.P.R., S.C.), Human Anatomy and Physiology, Section of Anatomy (P.G.A., G.A., A.S.B., G.G.N.), and Urology, School of Medicine (F.A.), University of Padua, 35121 Padua, Italy

Address all correspondence and requests for reprints to: Prof. G. G. Nussdorfer, Department of Human Anatomy and Physiology, Section of Anatomy, Via Gabelli 65, I-35121 Padova, Italy. E-mail: gastone.nusdorfer{at}unipd.it

Endothelin (ET)-1[1–21] stimulates steroid secretion and zona glomerulosa growth and is expressed in the human and rat adrenal cortex together with its receptor subtypes A and B (ETA and ETB). Although ET-1[1–21] is generated from bigET-1 by an ET-converting enzyme (ECE-1), there is evidence of an alternative chymase-mediated biosynthetic pathway leading to the production of an ET-1[1–31] peptide, the role of which in adrenal pathophysiology is largely unknown. Gene expression and immunohistochemical studies allowed localization of chymase in the normal human adrenal cortex. Sizable amounts, not only of ET-1[1–21] but also of ET-1[1–31], were found in the adrenal vein plasma of three patients. ET-1[1–21] and ET-1[1–31] elicited a clear-cut secretory response by dispersed human adrenocortical cells, ET-1[1–31] being significantly less potent than ET-1[1–21]. The secretagogue effect of ET-1[1–31] was abolished by the ETA receptor antagonist BQ-123 and was unaffected by the ETB receptor antagonist BQ-788. Because, in humans, the secretagogue effect of ET-1[1–21] involves both ETA and ETB receptors, the weaker action of ET-1[1–31] could be attributable to a selective ETA receptor activation. Two lines of evidence support this contention: 1) ET-1[1–31] was more effective than ET-1[1–21] in stimulating ETA-mediated cell proliferation of human adrenocortical cells cultured in vitro; and 2) autoradiography showed that a) ET-1[1–31] displaced in vitro [¹²⁵I]ET-1[1–21] binding to the ETA, but not ETB receptors, in human internal thoracic artery rings; and b) BQ-123, but not BQ-788, eliminated [¹²⁵I]ET-1[1–31] binding in the rat adrenal cortex.

Abbreviations: BrdU, 5-Bromo-2'-deoxyuridine; ECE, ET-converting enzyme; ET, endothelin; RT, reverse transcription; VSMC, vascular smooth muscle cells; ZF/R, zona fasciculata-reticularis; ZG, zona glomerulosa.

This article has been cited by other articles:

				M. O. van Aken, A. M Pereira, S. W. van Thiel, G. van den Berg, M. Frolich, J. D. Veldhuis, J. A. Romijn, and F. Roelfsema Irregular and Frequent Cortisol Secretory Episodes with Preserved Diurnal Rhythmicity in Primary Adrenal Cushing's Syndrome J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1570 - 1577. [Abstract] [Full Text] [PDF]